הלוואות ואשראי לטווח ארוך של החברה: Retrophin (TVTX)

Travere Therapeutics (TVTX) ensures the seamless supply of medications through a network of specialized distributors. The company focuses on developing life-saving drugs for patients with orphan kidney diseases. Stable revenue is supported by portfolio diversification within narrow therapeutic niches. The issuer's long-term liabilities metric on GURU.Markets reflects the financial leverage, where 0.57 represents the most recent value of the metric.

Long-term liabilities measure the aggregate of loans with maturities exceeding one year, reflecting the strategic financial leverage and the company's ability to raise capital for scaling. By analyzing the volume of the issuer's long-term liabilities, an investor assesses the credit stability of Travere Therapeutics (TVTX), whose investments in combating rare kidney pathologies and retaining highly qualified scientists require balanced debt financing.